FILINGS
| GLAXF 0001131399 | |||
|---|---|---|---|
| Filing Date | Form Type | Description | Document |
| 2025-03-24 | 6-K | TRANSACTION IN OWN SHARES | View Document |
| 2025-03-21 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2025-03-21 | 6-K | TRANSACTION IN OWN SHARES | View Document |
| 2025-03-20 | 6-K | TRANSACTION IN OWN SHARES | View Document |
| 2025-03-19 | 6-K | TRANSACTION IN OWN SHARES | View Document |
| 2025-03-18 | CERT | NYSE CERTIFICATION | View Document |
| 2025-03-18 | CERT | NYSE CERTIFICATION | View Document |
| 2025-03-18 | 6-K | TRANSACTION IN OWN SHARES | View Document |
| 2025-03-17 | 6-K | TRANSACTION IN OWN SHARES | View Document |
| 2025-03-14 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2025-03-14 | 6-K | TRANSACTION IN OWN SHARES | View Document |
| 2025-03-13 | 8-A12B | 8-A12B | View Document |
| 2025-03-13 | 8-A12B | 8-A12B | View Document |
| 2025-03-13 | 6-K | 6-K | View Document |
| 2025-03-13 | 6-K | TRANSACTION IN OWN SHARES | View Document |
| 2025-03-12 | 6-K | TRANSACTION IN OWN SHARES | View Document |
| 2025-03-11 | 6-K | TRANSACTION IN OWN SHARES | View Document |
| 2025-03-10 | 424B2 | 424B2 | View Document |
| 2025-03-10 | 6-K | TRANSACTION IN OWN SHARES | View Document |
| 2025-03-07 | SCHEDULE 13G/A | View Document | |
| 2025-03-07 | 6-K | TRANSACTION IN OWN SHARES | View Document |
| 2025-03-07 | FWP | FWP | View Document |
| 2025-03-06 | 424B2 | 424B2 | View Document |
| 2025-03-06 | 6-K | TRANSACTION IN OWN SHARES | View Document |
| 2025-03-05 | 6-K | TRANSACTION IN OWN SHARES | View Document |
| 2025-03-04 | 6-K | TRANSACTION IN OWN SHARES | View Document |
| 2025-03-03 | 6-K | GSK PLC 2024 ANNUAL REPORT ON FORM 20-F | View Document |
| 2025-03-03 | IRANNOTICE | IRANNOTICE | View Document |
| 2025-03-03 | 20-F | 20-F | View Document |
| 2025-03-03 | 6-K | TOTAL VOTING RIGHTS | View Document |
| 2025-03-03 | 6-K | US FDA ACCEPT 2 DEPEMOKIMAB INDICATION SUBMISSIONS | View Document |
| 2025-03-03 | 6-K | ANCHOR RESULTS PRESENTED AT 2025 AAAAI | View Document |
| 2025-03-03 | 6-K | TRANSACTION IN OWN SHARES | View Document |
| 2025-02-28 | 6-K | TRANSACTION IN OWN SHARES | View Document |
| 2025-02-27 | 6-K | TRANSACTION IN OWN SHARES | View Document |
| 2025-02-27 | 6-K | GSK PUBLISHES ANNUAL REPORT 2024 | View Document |
| 2025-02-26 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2025-02-26 | 6-K | TRANSACTION IN OWN SHARES | View Document |
| 2025-02-25 | 6-K | TRANSACTION IN OWN SHARES | View Document |
| 2025-02-24 | 6-K | GSK COMPLETES ACQUISITION OF IDRX, INC. | View Document |
| 2025-02-24 | 6-K | GSK PLC COMMENCES SHARE BUYBACK PROGRAMME | View Document |
| 2025-02-21 | 6-K | DIRECTORATE CHANGE | View Document |
| 2025-02-21 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2025-02-21 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2025-02-21 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2025-02-21 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2025-02-21 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2025-02-21 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2025-02-20 | 6-K | NUCALA COPD SUBMISSION ACCEPTED IN CHINA | View Document |
| 2025-02-18 | 6-K | GSK 5-IN-1 MENINGITIS VACCINE APPROVED BY US FDA | View Document |
| 2025-02-13 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2025-02-11 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2025-02-05 | 6-K | FINAL RESULTS | View Document |
| 2025-02-03 | 6-K | TOTAL VOTING RIGHTS | View Document |
| 2025-01-28 | 6-K | DEPEMOKIMAB DUAL FILING IN CHINA AND JAPAN | View Document |
| 2025-01-28 | 6-K | EMA ACCEPTS TWO SUBMISSIONS FOR DEPEMOKIMAB | View Document |
| 2025-01-27 | 6-K | EMA ACCEPT REVIEW SHINGRIX SYRINGE PRESENTATION | View Document |
| 2025-01-21 | 6-K | JEMPERLI EXPANDED APPROVAL IN THE EU | View Document |
| 2025-01-16 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2025-01-15 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2025-01-14 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2025-01-13 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2025-01-13 | 6-K | GSK ENTERS AGREEMENT TO ACQUIRE IDRX, INC. | View Document |
| 2025-01-10 | 6-K | SHINGRIX FULLY LIQUID ACCEPTED FOR US FDA REVIEW | View Document |
| 2025-01-07 | 6-K | GSK ADC GETS FDA BREAKTHROUGH THERAPY DESIGNATION | View Document |
| 2025-01-03 | 6-K | GSK'S NUCALA APPROVED IN CHINA FOR USE IN CRSWNP | View Document |
| 2025-01-02 | 6-K | TOTAL VOTING RIGHTS | View Document |
| 2024-12-23 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2024-12-20 | 6-K | BLOCK LISTING APPLICATION | View Document |
| 2024-12-20 | 6-K | HEADLINE RESULTS FROM PHASE III FIRST TRIAL | View Document |
| 2024-12-16 | 6-K | JEMPERLI RECEIVES US FDA BREAKTHROUGH DESIGNATION | View Document |
| 2024-12-16 | 6-K | EMA GRANTS PRIME DESIGNATION FOR GSK 227 | View Document |
| 2024-12-16 | 6-K | JEMPERLI RECEIVES POSITIVE CHMP OPINION | View Document |
| 2024-12-12 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2024-12-09 | 6-K | OVERALL SURVIVAL DATA PRESENTED FOR BLENREP | View Document |
| 2024-12-09 | 6-K | BLENREP COMBINATION CHINA FILING ACCEPTANCE | View Document |
| 2024-12-09 | 6-K | NUCALA COPD SUBMISSION ACCEPTED BY US FDA | View Document |
| 2024-12-05 | 6-K | ZHIFEI CHINA COLLABORATION REVISED AND EXTENDED | View Document |
| 2024-12-02 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2024-12-02 | 6-K | TOTAL VOTING RIGHTS | View Document |
| 2024-11-27 | 6-K | GSK LIQUID MENINGITIS VACCINE AUTHORISED IN EU | View Document |
| 2024-11-25 | 6-K | BLENREP COMBINATIONS ACCEPTED FOR US FDA REVIEW | View Document |
| 2024-11-22 | 6-K | JAPAN APPROVES FIRST RSV VACCINE FOR ADULTS 50-59 | View Document |
| 2024-11-19 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2024-11-19 | 6-K | GLISTEN TRIAL OF LINERIXIBAT MEETS ENDPOINT | View Document |
| 2024-11-15 | SC 13D/A | AMENDMENT TO THE SCHEDULE 13D | View Document |
| 2024-11-14 | 6-K | GSK ANNOUNCES OVERALL SURVIVAL RESULTS FOR BLENREP | View Document |
| 2024-11-13 | 6-K | BLOCK LISTING INTERIM REVIEW | View Document |
| 2024-11-12 | SC 13G/A | AMENDMENT TO FORM SC 13G | View Document |
| 2024-11-12 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2024-11-12 | 6-K | GSK PUBLISHES PROVISIONAL 2025 DIVIDEND DATES | View Document |
| 2024-11-01 | 6-K | TOTAL VOTING RIGHTS | View Document |
| 2024-10-30 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2024-10-30 | 6-K | 3RD QUARTER RESULTS | View Document |
| 2024-10-24 | 6-K | NEW POSITIVE AREXVY DATA IN YOUNGER ADULTS AT RISK | View Document |
| 2024-10-17 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2024-10-16 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2024-10-16 | 6-K | FDA ACCEPTS NEW DRUG APPLICATION FOR GEPOTIDACIN | View Document |
| 2024-10-15 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2024-10-15 | 6-K | POSITIVE RESULTS OF ANCHOR TRIALS OF DEPEMOKIMAB | View Document |
Search company filings and access detailed reports including 10-K, 10-Q, 8-K, and other critical filings. Stay informed on corporate disclosures, regulatory filings, and updates with our easy-to-use EDGAR API filings search tool.
